Urogenital chlamydia trachomatis treatment failure with azithromycin: A meta-analysis
Background Chlamydia Trachomatis is one of the most common pathogens transmitted through the genital tract in humans that leads to urogenital infection. Objective Given the high prevalence of chlamydia infection and its adverse effects on the health of women and men...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Shahid Sadoughi University of Medical Sciences
2019-09-01
|
Series: | International Journal of Reproductive BioMedicine |
Subjects: | |
Online Access: | https://doi.org/10.18502/ijrm.v17i9.5093 |
id |
doaj-d118312f914740f69b0f2a3805eac818 |
---|---|
record_format |
Article |
spelling |
doaj-d118312f914740f69b0f2a3805eac8182021-06-17T08:42:00ZengShahid Sadoughi University of Medical SciencesInternational Journal of Reproductive BioMedicine2476-37722019-09-011760362010.18502/ijrm.v17i9.5093Urogenital chlamydia trachomatis treatment failure with azithromycin: A meta-analysisFarnaz Mohammadzadeh0Mahrokh Dolatian1Masoumeh Jorjani2Maryam Afrakhteh3Hamid Alavi Majd4Fatemeh Abdi5Reza Pakzad6 Faculty of Health, Ilam University of Medical Sciences, Ilam, Iran Faculty of Health, Ilam University of Medical Sciences, Ilam, Iran Faculty of Health, Ilam University of Medical Sciences, Ilam, Iran Faculty of Health, Ilam University of Medical Sciences, Ilam, Iran Faculty of Health, Ilam University of Medical Sciences, Ilam, Iran Faculty of Health, Ilam University of Medical Sciences, Ilam, Iran Faculty of Health, Ilam University of Medical Sciences, Ilam, Iran Background Chlamydia Trachomatis is one of the most common pathogens transmitted through the genital tract in humans that leads to urogenital infection. Objective Given the high prevalence of chlamydia infection and its adverse effects on the health of women and men, the present meta-analysis was conducted to determine the rate of treatment failure with azithromycin. Materials and Methods Databases including MEDLINE, ISI - Web of Science, PubMed, EMBASE, Scopus, ProQuest, and Science Direct were searched for articles published between 1991 and 2018. The quality of the selected articles was assessed using the Cochrane risk of bias assessment tool. Heterogeneity was determined using the I2 and Cochrane Q-Test. Subgroup analysis and meta-regression were used to compare the prevalence rates on different levels of the variables. Results A total of 21 articles that met the inclusion criteria were ultimately assessed. The pooled estimate of azithromycin failure rate was 11.23% (CI 95%: 8.23%-14.24%). Also, the azithromycin failure rate was 15.87% (CI 95%: 10.20%-21.54%) for the treatment of urethritis, 7.41% (CI 95%: 0.60%-14.22%) for cervicitis, and 7.14% (CI 95%: 10.90%-3.39%) for genital chlamydia. The pooled estimate of failure rate difference was 2.37% (CI 95%: 0.68%-4.06%), which shows that azithromycin has a higher failure rate in the treatment of chlamydia compared to doxycycline and other examined medications. The meta-regression results showed that the patient's age contributes significantly to the heterogeneity for azithromycin treatment failure rate (β░=░0.826; p░=░0.017). Conclusion Azithromycin has a higher failure rate than doxycycline and other studied medications in treating urogenital chlamydia infections.https://doi.org/10.18502/ijrm.v17i9.5093azithromycinchlamydia trachomatisurogenitaltreatment failuremeta-analysis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Farnaz Mohammadzadeh Mahrokh Dolatian Masoumeh Jorjani Maryam Afrakhteh Hamid Alavi Majd Fatemeh Abdi Reza Pakzad |
spellingShingle |
Farnaz Mohammadzadeh Mahrokh Dolatian Masoumeh Jorjani Maryam Afrakhteh Hamid Alavi Majd Fatemeh Abdi Reza Pakzad Urogenital chlamydia trachomatis treatment failure with azithromycin: A meta-analysis International Journal of Reproductive BioMedicine azithromycin chlamydia trachomatis urogenital treatment failure meta-analysis |
author_facet |
Farnaz Mohammadzadeh Mahrokh Dolatian Masoumeh Jorjani Maryam Afrakhteh Hamid Alavi Majd Fatemeh Abdi Reza Pakzad |
author_sort |
Farnaz Mohammadzadeh |
title |
Urogenital chlamydia trachomatis treatment failure with azithromycin: A meta-analysis |
title_short |
Urogenital chlamydia trachomatis treatment failure with azithromycin: A meta-analysis |
title_full |
Urogenital chlamydia trachomatis treatment failure with azithromycin: A meta-analysis |
title_fullStr |
Urogenital chlamydia trachomatis treatment failure with azithromycin: A meta-analysis |
title_full_unstemmed |
Urogenital chlamydia trachomatis treatment failure with azithromycin: A meta-analysis |
title_sort |
urogenital chlamydia trachomatis treatment failure with azithromycin: a meta-analysis |
publisher |
Shahid Sadoughi University of Medical Sciences |
series |
International Journal of Reproductive BioMedicine |
issn |
2476-3772 |
publishDate |
2019-09-01 |
description |
Background
Chlamydia Trachomatis is one of the most common pathogens transmitted through the genital tract in humans that leads to urogenital infection.
Objective
Given the high prevalence of chlamydia infection and its adverse effects on the health of women and men, the present meta-analysis was conducted to determine the rate of treatment failure with azithromycin.
Materials and Methods
Databases including MEDLINE, ISI - Web of Science, PubMed, EMBASE, Scopus, ProQuest, and Science Direct were searched for articles published between 1991 and 2018. The quality of the selected articles was assessed using the Cochrane risk of bias assessment tool. Heterogeneity was determined using the I2 and Cochrane Q-Test. Subgroup analysis and meta-regression were used to compare the prevalence rates on different levels of the variables.
Results
A total of 21 articles that met the inclusion criteria were ultimately assessed. The pooled estimate of azithromycin failure rate was 11.23% (CI 95%: 8.23%-14.24%). Also, the azithromycin failure rate was 15.87% (CI 95%: 10.20%-21.54%) for the treatment of urethritis, 7.41% (CI 95%: 0.60%-14.22%) for cervicitis, and 7.14% (CI 95%: 10.90%-3.39%) for genital chlamydia. The pooled estimate of failure rate difference was 2.37% (CI 95%: 0.68%-4.06%), which shows that azithromycin has a higher failure rate in the treatment of chlamydia compared to doxycycline and other examined medications. The meta-regression results showed that the patient's age contributes significantly to the heterogeneity for azithromycin treatment failure rate (β░=░0.826; p░=░0.017).
Conclusion
Azithromycin has a higher failure rate than doxycycline and other studied medications in treating urogenital chlamydia infections. |
topic |
azithromycin chlamydia trachomatis urogenital treatment failure meta-analysis |
url |
https://doi.org/10.18502/ijrm.v17i9.5093 |
work_keys_str_mv |
AT farnazmohammadzadeh urogenitalchlamydiatrachomatistreatmentfailurewithazithromycinametaanalysis AT mahrokhdolatian urogenitalchlamydiatrachomatistreatmentfailurewithazithromycinametaanalysis AT masoumehjorjani urogenitalchlamydiatrachomatistreatmentfailurewithazithromycinametaanalysis AT maryamafrakhteh urogenitalchlamydiatrachomatistreatmentfailurewithazithromycinametaanalysis AT hamidalavimajd urogenitalchlamydiatrachomatistreatmentfailurewithazithromycinametaanalysis AT fatemehabdi urogenitalchlamydiatrachomatistreatmentfailurewithazithromycinametaanalysis AT rezapakzad urogenitalchlamydiatrachomatistreatmentfailurewithazithromycinametaanalysis |
_version_ |
1721374233900089344 |